Rodman & Renshaw analyst Michael King Jr. initiates coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Buy rating and a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot New Coverage New Coverage